Leica Microsystems acquires Coretech Holdings Scientific

Leica Microsystems announced in May it acquired the assets of St. Louis, Missouri-based Coretech Holdings and McCormick Scientific, LLC (Coretech), expanding its leading position in histopathology. Coretech provides an extensive range of systems, instruments, reagents and consumables for the clinical and research histology laboratory.

Anne De Greef-Safft, President of Leica Microsystems’ Biosystems Division.
Anne De Greef-Safft, President of Leica Microsystems’ Biosystems Division.
Coretech is comprised of a suite of strong brands including: McCormick Scientific, The Vibratome Company, Paraplast embedding media, TurbOflow II histology cassettes and myNeuroLab.com.
Coretech becomes a business unit within the Biosystems Division, and will be renamed Leica
Biosystems St. Louis, LLC. said Doug Martin, formerly CEO of Coretech Holdings, LLC and now Vice President & General Manager of Leica Biosystems St. Louis, LLC, “The synergies created by combining the Coretech products and team with those of Leica Microsystems are considerable. Both companies will quickly leverage an improved product offering for our customers and expand our ability to service the needs of our customers.”
 
“With this acquisition, Leica Microsystems continues to broaden and strengthen the product line we offer our customers. The benefit to customers is that they now have a single partner to come to for all their histology equipment, reagent and consumable needs. Having internal research and development, as well as manufacturing capabilities for the instrument and their associated reagents and consumables allows us to better optimize the entire system, leading to higher quality and more consistent results for our customers,” says Anne De Greef-Safft, President of Leica Microsystems’ Biosystems Division.

17.06.2008

More on the subject:
Read all latest stories

Related articles

Photo

News • Economic burden of CVD

Putting a price tag on cardiovascular disease in Europe

Cardiovascular disease (CVD) cost the EU an estimated €282 billion in 2021, according to late breaking research presented at the European Society of Cardiology's ESC Congress 2023.

Photo

News • Biopharmaceutical business

Precision approach to significantly reduce R&D costs for cancer drugs

A new analysis exploring the finances of bringing new cancer drugs to market has found that precision oncology drugs could be $1 billion cheaper to develop than non-precision drugs.

Photo

News • Economic and social rights

Women’s rights strongholds are healthier, study finds

Nations with strong women’s rights are more likely to have better health and faster growth than those who don’t promote and protect these values, finds research published in the online journal…

Related products

Subscribe to Newsletter